CN111848606A - Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formylglycine and alanine - Google Patents
Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formylglycine and alanine Download PDFInfo
- Publication number
- CN111848606A CN111848606A CN201910364847.0A CN201910364847A CN111848606A CN 111848606 A CN111848606 A CN 111848606A CN 201910364847 A CN201910364847 A CN 201910364847A CN 111848606 A CN111848606 A CN 111848606A
- Authority
- CN
- China
- Prior art keywords
- imidazo
- tetrahydro
- pyridine
- theanyl
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
The present invention discloses (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] of the formula]Pyridine-6-formyl AA (AA is glycine residue and L-alanine residue), discloses a preparation method thereof, discloses antithrombotic activity thereof, discloses thrombolytic activity thereof and discloses therapeutic effect thereof on ischemic stroke for 24 hours, so that the invention discloses application thereof in preparing antithrombotic medicaments, thrombolytic medicaments and medicaments for treating ischemic stroke for 24 hours.
Description
Technical Field
The present invention relates to (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-AA, to a process for their preparation, to their antithrombotic activity, to their thrombolytic activity and to their therapeutic effect on patients with ischemic stroke for 24 hours, and thus to their use in the preparation of antithrombotic agents, thrombolytic agents and agents for treating ischemic stroke for 24 hours. The invention belongs to the field of biological medicine.
Technical Field
Ischemic stroke is a common, severely damaging cerebrovascular disease. Ischemic stroke is characterized by high morbidity, high disability rate, high recurrence rate and high mortality rate, and is one of the most serious fatal diseases for human beings. Currently, rtPA is the only clinically accepted effective drug for the treatment of ischemic stroke. However, rtPA has two difficult problems to overcome in treating ischemic stroke. The first problem is that rtPA is not effective in patients with stroke over 4 hours. The second problem is that continued use of rtPA can cause bleeding in the brain, thorax and abdominal cavities. The invention is a hot point and a leading edge of research of cerebrovascular drugs, and is a drug which is effective on stroke for more than 4h, particularly on stroke for 24h patients and has no bleeding side effect.
The inventors have disclosed that spinacin derivatives of formula I have antithrombotic activity at an oral dose of 10nmol/kg (Pengzhi, Zhaoming, Strgerstroemia. amino acid modified spinacin derivatives, methods of preparation and use thereof, CN 102807600A [ P ]. 2011.). However, at this oral dose they show neither thrombolytic activity nor effect in treating ischemic stroke.
The inventor has disclosed that the intravenous administration of the spinacin derivative of the following formula II at a dose of 1nmol/kg can reduce the cerebral infarction volume of rats with ischemic stroke (Peng Shi Qi, Zhao Ming, Wang Yu Shi, Wu Jian Hui, Cao He. cyclyl-KAK, its synthesis, thrombus related activity and application, CN 106317186A [ P ] 2017.). However, it has no effect on rats with ischemic stroke for more than 4h at this intravenous dose.
In a further structural modification, the inventors found that a compound obtained by introducing a theanyl group to the amino group of the spinacin derivative of the above formula I and substituting the AA with a glycine residue and an L-alanine residue was not only effective in rats with 24h stroke but also free from bleeding side effects. In light of this finding, the inventors have devised the present invention.
Disclosure of Invention
The first aspect of the present invention provides (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-AA (AA is a glycine residue and an L-alanine residue) of the formula.
The second aspect of the present invention provides a method for synthesizing (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-AA (AA is glycine and L-alanine residues), which comprises:
(1) preparing (6S) -4,5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylic acid;
(2) preparing (6S) -methyl 4,5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylate;
(3) preparing (6S) -5-tert-butoxycarbonyl-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylic acid methyl ester;
(4) preparing (6S) -5-tert-butoxycarbonyl-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylic acid;
(5) preparing (6S) -5-tert-butoxycarbonyl-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-AA benzyl ester (AA is glycine residue and L-alanine residue);
(6) Preparing (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-AA benzyl ester (AA is glycine and L-alanine residue);
(7) preparation of (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-AA (AA is glycine residue, L-alanine residue).
The third aspect of the present invention is to evaluate the antithrombotic activity, thrombolytic activity and activity for treating ischemic stroke of (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-AA (AA is glycine residue, L-alanine residue).
Drawings
FIG. 1(6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c]A synthetic route to pyridine-6-formyl-AA (AA is an alanine residue (7a) and a glycine residue (7 b)). i) HCHO, H2O, concentrated H2SO4；ii)CH3OH,SOCl2(ii) a iii) anhydrous DMF, Boc-The, HATU, NMM; iv)2N NaOH; v) AA-OBzl, DCC, HOBt, NMM; vi) a solution of hydrogen chloride in ethyl acetate (4M); vii) H2/Pd。
Detailed Description
To further illustrate the invention, a series of examples are given below. These examples are purely illustrative and are intended to be a detailed description of the invention only and should not be taken as limiting the invention.
EXAMPLE 1 preparation of (6S) -4,5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylic acid (1)
A mixture of 10.0g (64.5mmol) L-His with 80mL distilled water was sonicated to a suspension. To this suspension was slowly added dropwise 2mL of concentrated sulfuric acid at 0 ℃ with stirring. After that, 20mL of an aqueous formaldehyde solution (40%) was added. The reaction mixture was reacted at 60 ℃ for 7h and then cooled to room temperature. Adjusting the pH value of the reaction mixture to 6 by using stronger ammonia water at 0 ℃ under stirring, and standing to ensure that the product is fully separated out. The precipitated product was filtered off and dried to yield 7.4g (69%) of the title compound as a colorless solid.
EXAMPLE 2 preparation of (6S) -methyl 4,5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylate (2)
After 7.8mL of thionyl chloride was slowly dropped into 120mL of methanol at 0 ℃ with stirring, activation was carried out for 30 minutes, 5.09g (30.4mmol) of (6S) -4,5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylic acid was added thereto, and the mixture was stirred at room temperature for 72 hours, the reaction mixture was concentrated under reduced pressure, and the residue was diluted with methanol and concentrated under reduced pressure. This operation was repeated three times. 7.4g (96%) of the title compound are obtained as a colorless solid.
EXAMPLE 3 preparation of t-Butoxycarbonylphenyltheanine
3.6g (20.7mmol) of theanine was dissolved in 30mL of distilled water, and the resulting aqueous solution was diluted with 30mL of dioxane, and 5.5g (25.2mmol) (Boc) was added2O, the reaction mixture was adjusted to pH 9 with 2N NaOH at 0 ℃ with stirring, and the pH of the reaction solution was maintained at 9 with 2N NaOH. Stirring at room temperature for 96 hours After the reaction, slowly dropwise adding saturated KHSO at 0 ℃ while stirring4Adjusting pH of the aqueous solution to neutral, and concentrating under reduced pressure to remove dioxane. The residue was adjusted to pH 2 with saturated aqueous potassium hydrogensulfate solution, extracted with ethyl acetate (40 mL. times.3), the combined ethyl acetate layers were washed 3 times with saturated aqueous sodium chloride solution, dried with anhydrous sodium sulfate for 12 hours, filtered, and the filtrate was concentrated to dryness under reduced pressure to give 4.8g (85%) of the title compound.
EXAMPLE 4 preparation of methyl (6S) -5-tert-Butoxycarbonylphosphinyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylate (3)
3.1g (11.3mmol) of t-butoxycarbonyltheanine and 2.87g (11.3mmol) of (6S) -4,5,6, 7-tetrahydro-3H-imidazo [4, 5-c)]Methyl bipyridine-6-carboxylate was dissolved in anhydrous N, N-Dimethylformamide (DMF), 4.7g (12.4mmol) of 2- (7-azobenzotriazol) -N, N, N ', N' -tetramethyluronium Hexafluorophosphate (HATU) was added with stirring at 0 deg.C, and then pH was adjusted to 9 with N-methylmorpholine (NMM). Stir at room temperature for 8h, then concentrate under reduced pressure to remove DMF. The residue was dissolved in ethyl acetate, and the resulting solution was washed with saturated aqueous sodium bicarbonate solution 2 times, then with saturated aqueous sodium chloride solution 2 times, and the ethyl acetate layer solution was dried over anhydrous sodium sulfate for 12 hours, filtered, and the filtrate was concentrated under reduced pressure to dryness to give a yellow oil which was subjected to silica gel column chromatography to give 3.6 g (73%) of the title compound as a colorless solid. ESI-MS (M/z):438[ M + H ]+。1H NMR(DMSO-d6,300MHz) /ppm＝11.94(s,1H),7.79(t,J＝6.0Hz,1H),7.53(d,J＝6.0Hz,1H),7.07(m,1H),5.71(m, 1H),4.81(m,1H),4.41(m,1H),3.58(d,J＝6.0Hz,3H),3.40-2.84(m,4H),2.22-1.64(m,4 H),1.35(d,J＝6.0Hz,9H),1.01(m,3H)。
EXAMPLE 5 preparation of (6S) -5-tert-Butoxycarbonylphosphinyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylic acid (4)
1.2g (2.7mmol) of (6S) -5-tert-butoxycarbonyltheanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4, 5-c)]Dissolving pyridine-6-methyl formate in methanol, adding 10mL NaOH methanol solution (2M) at 0 deg.C under stirring, reacting for 2 hr, and slowly adding saturated KHSO dropwise4Adjusting pH of the aqueous solution to neutral, filtering to remove precipitated salt, concentrating the filtrate under reduced pressure, dissolving the residue with 20mL anhydrous ethanol, filtering to remove insoluble salt, and filtering the filtrate under reduced pressureConcentration to dryness gave 1.12g (93%) of the title compound as a colourless solid. ESI-MS (M/z):422[ M-H]-。
EXAMPLE 6 preparation of (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylic acid (4')
0.48g (1.13mmol) of (6S) -5-tert-butoxycarbonyl-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] is stirred at 0 deg.C]Dissolving pyridine-6-carboxylic acid in 6mL of ethyl acetate solution (4M) of hydrogen chloride, reacting at room temperature for 4h, concentrating the reaction solution under reduced pressure, adding a proper amount of anhydrous ethyl acetate into the residue, dissolving, and draining. This operation was repeated three times to give 0.15g (33%) of the title compound as a colorless powder. ESI-MS (M/e):324[ M + H]+。1H NMR(DMSO-d6,300MHz)/ppm＝8.46(s, 2H),7.84(m,1H),7.55(d,1H),5.10(d,J＝15Hz,1H),4.21(m,1H),3.94(m,2H),3.06-2.69 (m,4H),2.19-1.91(m,4H),0.97(m,3H)。
EXAMPLE 7 preparation of (6S) -5-tert-Butoxycarbonylphosphinyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-L-alanine benzyl ester (5a)
1.02g (2.4mmol) of (6S) -5-tert-butoxycarbonyltheanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4, 5-c)]Dissolving pyridine-6-carboxylic acid with 20mL of anhydrous tetrahydrofuran, sequentially adding 0.46g (3.4mmol) of N-hydroxy benzotriazole (HOBt) and 0.7g (3.4mmol) of N, N-dicyclohexyl carbodiimide (DCC) solution dissolved with the anhydrous tetrahydrofuran at 0 ℃ under stirring, and fully stirring for 30 minutes to obtain a solution A; 0.99g (2.8mmol) of Tos. Ala-OBzl dissolved in 20mL of anhydrous tetrahydrofuran was added to the reaction solution A, and the pH was adjusted to 9 with N-methylmorpholine. After stirring at room temperature for 8 hours, the mixture was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate, and insoluble matter was filtered off. The ethyl acetate layer was washed successively with a saturated aqueous solution of sodium hydrogencarbonate 3 times and saturated aqueous solution of sodium chloride 3 times, dried over anhydrous sodium sulfate for 12 hours, filtered, the resulting filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give 0.6g (36%) of the title compound as a colorless powder. ESI-MS (M/e):585[ M + H]+。1H NMR (DMSO-d6,300MHz)/ppm＝11.84(s,1H),8.32(m,1H),7.84(d,J＝6.0Hz,1H)7.48(d,J＝ 6.0Hz,1H),7.31(m,5H),5.51(m,1H),5.03(m,2H),4.57(m,2H),4.31(m,1H),3.24-2.76 (m,4H),2.17-1.66(m,4H),1.35(m,9H),1.24(m,3H),1.01(m,3H)。
EXAMPLE 8 preparation of (6S) -5-tert-Butoxycarbonylphenyll-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-glycine benzyl ester (5b)
From 0.6g (1.4mmol) of (6S) -5-tert-butoxycarbonyl-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] using the method of example 7 ]And pyridine-6-carboxylic acid and 0.48g (1.4mmol) of tos.Gly-OBzl gave 0.6g (38%) of the title compound as a colorless powder. ESI-MS (M/e) 588[ M + H ]]+。1H NMR(DMSO-d6,300MHz)/ppm＝11.87(s,1H),8.35(d,J＝ 6.0Hz,1H),7.87(d,J＝6.0Hz,1H),7.48(d,J＝6.0Hz,1H),7.32(m,5H),5.51(m,1H), 5.03(s,2H),4.57(m,2H),4.31(m,1H),3.26-2.73(m,4H),2.15-1.55(m,4H),1.34(m,9H), 1.01(m,3H)。
EXAMPLE 9 preparation of (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-L-alanine benzyl ester (6a)
0.1g (0.18mmol) of (6S) -5-tert-butoxycarbonyl-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] is stirred at 0 deg.C]Dissolving pyridine-6-formyl-L-alanine benzyl ester by using 2mL of ethyl acetate solution (4M) of hydrogen chloride, reacting for 4 hours at room temperature, concentrating the reaction solution under reduced pressure, adding a proper amount of anhydrous ethyl acetate into residues for dissolving, and draining. This operation was repeated three times. 0.09g (95%) of the title compound are obtained as a colorless powder. ESI-MS (M/e):484[ M + H]+。
EXAMPLE 10 preparation of (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-glycine benzyl ester (6b)
From 0.152g (0.26mmol) of (6S) -5-tert-butoxycarbonyl-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] using the method of example 9]And pyridine-6-formyl-glycine benzyl ester gave 0.135g (93%) of the title compound as a colorless powder. ESI-MS (M/e): 471[ M + H]+。
EXAMPLE 11 preparation of (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-L-alanine (7a)
0.058g (0.1mmol) of (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4, 5-c-]Mixing pyridine-6-formyl-L-alanine benzyl ester with 10mg Pd/C, introducing hydrogen, stirring at room temperature for 4h, filtering to remove Pd/C, filtering to obtain filtrateConcentration under reduced pressure gave 0.047g (98%) of the title compound as a colorless solid. ESI-MS (M/e):395[ M + H]+；mp:206-207℃；
IR(cm-1):3245,2979,2935,2876,1716,1649,1540,1452,1384,1314, 1224,1150,1096,1054,937,883,629；1H NMR(DMSO-d6,300MHz)/ppm＝14.65(s,1H), 12.50(s,1H),8.94(s,1H),8.70(m,1H),8.58(s,2H),8.11(m,1H),5.51(m,1H),5.11(t,J＝ 15Hz,1H),4.57(m,2H),4.31(m,1H),3.35-2.90(m,4H),2.41-1.91(m,4H),1.30(t,J＝6Hz, 3H),1.01(m,3H)。
EXAMPLE 12 preparation of (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-glycine (7b)
From 0.1g (0.18mmol) of (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] using the method of example 11]And pyridine-6-formyl-glycine benzyl ester gave 0.08g (83%) of the title compound as a colorless solid. ESI-MS (M/e):381[ M + H]+；mp: 181-182℃；
IR(cm-1):3244,2979,2924,1729,1649,1539,1453, 1380,1351,1237,1197,1151,1040,997,972,946,883,803,746,686；1H NMR(DMSO-d6,300 MHz)/ppm＝14.74(s,1H),8.97(m,1H),8.59(s,2H),8.52(m,1H),8.10(m,1H),5.61(m,1 H),5.12(m,1H),4.56(m,1H),4.03(m,1H),3.85-3.50(m,2H),3.09(m,2H),2.40-1.91(m,4 H),1.01(m,3H)。
Experimental example 1 evaluation of antithrombotic Activity of Compounds 7a, b
Male SD rats (200. + -.20 g) were randomly divided into groups of 10 animals each, kept for 1 day and stopped overnight. Gavage administration of compound 4' (dose 1 μmol/kg) or (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-L-alanine (7a) and (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-L-glycine (7b) in physiological saline (dose 10nmol/kg) or aspirin in physiological saline (dose 167 μmol/kg) or physiological saline (dose 3 mL/kg). After 30min, rats were anesthetized with a 20% solution of uligose in physiological saline (7mL/kg) and then operated. The right carotid artery and the left jugular vein of the rat were isolated, accurately weighed silk was placed in the bypass cannula, one end of the tube was inserted into the left vein and the other end was inserted into the right artery and injected with 0.2mL heparin sodium anticoagulation. Allowing blood flow to flow from the right artery through the bypass cannula into the left vein, taking out the thread with thrombus after 15min, weighing, calculating the weight of the thread before and after blood circulation, and performing t-test to obtain the weight of the thrombus represented by the average value + -SD mg and representing the antithrombotic activity. The data are shown in Table 1. The results show that the oral administration of the 10nmol/kg compounds 7a and b can not only effectively inhibit the thrombosis, but also the activity has no significant difference with 1 mu mol/kg compound 4' and 167 mu mol/kg aspirin, thereby showing that the technical effect of the invention is obvious.
TABLE 1 antithrombotic Activity of Compounds 7a, b
n-10, a) P <0.01 compared to saline, P >0.05 compared to compound 4' and aspirin; b) p <0.05 compared to saline, P >0.05 compared to compound 4' and aspirin.
Experimental example 2 evaluation of thrombolytic Activity of Compounds 7a, b
SD rats (male, 200. + -.20 g) were anesthetized with an intraperitoneal injection of 20% gulose in physiological saline (7 mL/kg). Fixing the rat in a supine position after anesthesia, separating the right common carotid artery of the rat, clamping an artery clamp at the proximal end, respectively penetrating the proximal end and the distal end into an operation line, ligating the operation line at the distal end, inserting a tube at the distal end, loosening the artery clamp, taking out 1mL of arterial blood, and placing the arterial blood in a 1mL centrifuge tube. A vertically fixed rubber tube (5 mm long, 2.5mm inner diameter, 5.0mm outer diameter, tube bottom sealed with rubber plug, para membrane sealed) is injected with 0.1mL rat arterial blood, then a stainless steel blood plug fixing bolt (the thrombus fixing spiral is wound by a stainless steel wire with the diameter of 0.2mm, the spiral part is 10mm long, 15 spiral rings are contained, the diameter of the spiral ring is 1.0mm, the support handle is connected with the spiral, the length is about 7.0mm, and the support handle is in a question mark shape) is rapidly inserted into the tube.
The bypass cannula consists of three parts, wherein the middle section is a polyethylene rubber tube with the length of 60.0mm and the inner diameter of 3.5 mm; both ends are 100.0 mm long, and internal diameter 1.0mm, the same polyethylene pipe of external diameter 2.0mm, and this pipe one end is drawn into the sharp pipe, and is about 10.0mm long (being used for inserting rat carotid artery and vein), and the external diameter is 1.0mm, and the outside cover section of its other end is long for 7.0mm, and the external diameter is 3.5 mm's polyethylene pipe (in being used for inserting the polyethylene rubber tube in middle section), and the inner wall of 3 sections pipes all needs silanization (1% silicon oil ether solution). The thrombus-wrapped thrombus fixing spiral is placed in the middle section polyethylene rubber tube, and the other two ends of the rubber tube are respectively sleeved with the thickened ends of the two polyethylenes, so that blood leakage can be avoided in the circulating process. The tube was filled with a heparin normal saline solution (50IU/kg) through the tip end with a syringe to remove air bubbles for use.
The left external jugular vein of separation rat, proximal end and distal end penetrate the operation line respectively, and the blood vessel of ligature distal end cuts a osculum on the left external jugular vein that exposes, inserts the bypass pipeline taper pipe that has been prepared above-mentioned into left external jugular vein opening part by the osculum, keeps away from bypass pipe middle section (contains the thrombus fixed spiral of accurate weighing) internal thrombus fixed spiral simultaneously. An accurate amount of a physiological saline solution (50IU/kg) of heparin sodium was injected through the tip tube at the other end with a syringe, at which time the syringe was not removed from the polyethylene tube, and the flexible tube between the syringe and the polyethylene tube was clamped with an artery clamp. Stopping bleeding by an artery clamp at the proximal end of the right common carotid artery, ligating the distal end, cutting a small opening of the right common carotid artery at a position short of the artery clamp, pulling out the injector from the tip of the polyethylene tube, and inserting the tip of the polyethylene tube into the proximal end of the oblique opening of the artery. Both ends of the bypass pipeline are used for fixing the artery and the vein by using a No. 4 surgical suture.
Physiological saline (3mL/kg) or a physiological saline solution of urokinase (dosage is 20000IU/kg) or a physiological saline solution of compound 4' (dosage is 1000nmol/kg) or a physiological saline solution of compounds 7a, b (dosage is 10nmol/kg) is inserted into the proximal venous end far away from the thrombus fixing spiral by passing through the middle section of the bypass tube (containing the thrombus fixing spiral accurately weighed) by using a scalp needle, and the arterial clamp is loosened to allow blood flow from the artery to the vein through the bypass tube. The solution in the syringe is slowly injected into the blood, and acts on the spiral thrombus through the blood circulation in the order of vein-heart-artery. After 1h of blood circulation, the thrombus-immobilizing helix was removed from the bypass tube and accurately weighed. Calculating the weight difference of the thrombus before and after spiral blood circulation of the immobilized thrombus in the bypass duct of each rat, namely the thrombus weight loss. Data (mean. + -. SD mg) were subjected to a t-test. Loss of thrombus represents thrombolytic activity. The results in Table 2 show that the 10nmol/kg compounds 7a and b can not only effectively dissolve thrombus, but also have no significant difference in activity from 1000nmol/kg compounds 4' and 20000IU/kg urokinase, thereby showing that the technical effect of the invention is obvious.
TABLE 2 thrombolytic Activity of Compounds 7a, b
n-10, a) to physiological saline ratio P <0.05 to compound 4' and urokinase ratio P >0.05.
Experimental example 3 evaluation of therapeutic Effect of Compounds 7a, b on ischemic Stroke 24h rats
A2 cm long incision was made vertically in the middle of the neck of male SD rats (body weight 300. + -.20 g), and the right common carotid artery, external carotid artery and internal carotid artery were isolated along the intramuscular side edge of the sternocleidomastoid muscle. Respectively clamping the opening of the internal carotid artery and the proximal end of the common carotid artery by using a noninvasive artery clamp, ligating the distal end of the external carotid artery, cutting a small opening on the external carotid artery, loosening the artery clamp at the proximal end of the common carotid artery, taking 10 mu L of blood, and then clamping the proximal end of the common carotid artery by using the noninvasive artery clamp. The obtained 10. mu.L of blood was placed in a 1mLEP tube at normal temperature for 15 minutes to coagulate the blood, and then transferred to a-20 ℃ refrigerator and left overnight to make the blood clot firm. Rats were anesthetized with a 10% chloral hydrate (4mL/kg) by intraperitoneal injection. The blood clot was removed, 1mL of physiological saline was added, the blood clot was pounded with a steel spatula into small thrombus blocks of uniform size, a suspension of the small thrombus was prepared and transferred to a 1mL syringe. Loosening the artery clamp at the proximal end of the common carotid artery, slowly injecting 1mL of thrombus suspension into the brain of a rat from the external carotid artery of the rat to the proximal end through the internal carotid artery, then ligating the proximal end of the external carotid artery, and opening the internal carotid artery and the common carotid artery to obtain the artery clamp to restore blood flow. 3 drops of a physiological saline solution of penicillin (40mg/10mL) are dropped on the wound, and the wound is sutured and waits for recovery. The degree of neurological deficit was assessed by the Zealonga method 24 hours after the rats were awakened. Score 0 indicates no sign of neurological deficit, score 1 indicates that the intact forelimb cannot stretch, score 2 indicates walking to the intact side, score 3 indicates turning to the intact side and walking in a tail-end-collision manner, score 4 indicates that the disorder is not self-walking, and score 5 indicates death. And randomly grouped according to the scores. Rats were given 1 time per day a saline solution of compound 7a, b (dose 10nmol/kg) or t-PA (dose 3mg/kg) or saline (dose 3mL/kg) via tail vein injection at a dose of 3 mL/kg; injections were continued for 3 days, and scored daily. Death rate, effectual rate and cure rate of each group were calculated from the scores (death rate ═ death number/total number) × 100%, (effectual rate ═ number of the last day scored lower than the number of the last day scored before administration) × 100%, cure rate ═ number of the last day scored 0/total number × 100%). The results are shown in Table 3. The data in table 3 show that the mortality rate and the cure rate of the stroke rats treated by the compounds 7a and b are lower than those of physiological saline, which shows that the technical effect of the invention is obvious.
TABLE 3 neurobiological score of stroke 24 hours rats injected intravenously 7a, b 1 time daily for 3 days
From the above data, it can be seen that the compound of the present invention has both antithrombotic activity, thrombolytic activity and 24h ischemic stroke treatment activity, i.e., 10nmol/kg of compound 7a can be orally administered once, b can effectively inhibit thrombosis, 10nmol/kg of compound 7a can be injected once, b can effectively dissolve thrombus, 10nmol/kg of compound 7a can be intravenously administered once a day for 4 days continuously, b can effectively recover neurobiological behavior of rats with ischemic stroke for 24h, can effectively reduce death rate of rats with ischemic stroke, increase survival rate thereof, and has no bleeding side effect. Compared with the compounds disclosed once, the compounds of the invention have outstanding technical effects.
Claims (5)
1. theacyltetrahydro-3H-imidazopyridine-6-formyl AA of the formula, wherein AA is a glycine residue and an L-alanine residue,
2. a process for the preparation of theacyltetrahydro-3H-imidazopyridine-6-formyl AA of claim 1, comprising the seven steps of:
(1) preparing (6S) -4,5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylic acid;
(2) preparing (6S) -methyl 4,5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylate;
(3) Preparing (6S) -5-tert-butoxycarbonyl-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylic acid methyl ester;
(4) preparing (6S) -5-tert-butoxycarbonyl-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylic acid;
(5) preparing (6S) -5-tert-butoxycarbonyl-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl-AA-OBzl;
(6) preparing (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-formyl AA-OBzl;
(7) preparation of (6S) -5-theanyl-4, 5,6, 7-tetrahydro-3H-imidazo [4,5-c ] pyridine-6-carboxylic acid A.
3. Use of theacyltetrahydro-3H-imidazopyridine-6-carboxylic acid as defined in claim 1 for the preparation of an antithrombotic medicament.
4. Use of theacyltetrahydro-3H-imidazopyridine-6-carboxylic acid amide according to claim 1 for the preparation of a thrombolytic drug.
5. Use of theacyltetrahydro-3H-imidazopyridine-6-carboxylic acid amide according to claim 1 for the preparation of a medicament for the treatment of ischemic stroke for 24 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910364847.0A CN111848606B (en) | 2019-04-30 | 2019-04-30 | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formylglycine and alanine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910364847.0A CN111848606B (en) | 2019-04-30 | 2019-04-30 | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formylglycine and alanine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111848606A true CN111848606A (en) | 2020-10-30 |
| CN111848606B CN111848606B (en) | 2023-03-21 |
Family
ID=72965134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910364847.0A Active CN111848606B (en) | 2019-04-30 | 2019-04-30 | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formylglycine and alanine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111848606B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102796167A (en) * | 2011-05-26 | 2012-11-28 | 首都医科大学 | (S)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-formyl-L-prolyl-L-alanyl-L-amino acid, and preparation method and application thereof |
| CN102807600A (en) * | 2011-06-03 | 2012-12-05 | 首都医科大学 | Amino acid modified spinacin derivative and preparation method and application thereof |
| CN106317186A (en) * | 2015-06-23 | 2017-01-11 | 首都医科大学 | Cyclic histidyl-KAK, synthesis, thrombus-associated activity and application thereof |
| CN108348894A (en) * | 2015-09-20 | 2018-07-31 | 空气交叉股份有限公司 | For compound activating and the ozonolysis of ozone degradation |
| CN108976225A (en) * | 2017-05-31 | 2018-12-11 | 首都医科大学 | The spinacin of Polar Amides acid benzyl ester modification, its synthesis, activity rating and application |
-
2019
- 2019-04-30 CN CN201910364847.0A patent/CN111848606B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102796167A (en) * | 2011-05-26 | 2012-11-28 | 首都医科大学 | (S)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-formyl-L-prolyl-L-alanyl-L-amino acid, and preparation method and application thereof |
| CN102807600A (en) * | 2011-06-03 | 2012-12-05 | 首都医科大学 | Amino acid modified spinacin derivative and preparation method and application thereof |
| CN106317186A (en) * | 2015-06-23 | 2017-01-11 | 首都医科大学 | Cyclic histidyl-KAK, synthesis, thrombus-associated activity and application thereof |
| CN108348894A (en) * | 2015-09-20 | 2018-07-31 | 空气交叉股份有限公司 | For compound activating and the ozonolysis of ozone degradation |
| CN108976225A (en) * | 2017-05-31 | 2018-12-11 | 首都医科大学 | The spinacin of Polar Amides acid benzyl ester modification, its synthesis, activity rating and application |
Non-Patent Citations (2)
| Title |
|---|
| CONATO, C.等: "Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity", 《BIOCHIMICA ET BIOPHYSICA ACTA, GENERAL SUBJECTS》 * |
| 潘琪: "5,6,7,8-四氢咪唑[1,2-a]吡啶-3-硼酸盐酸盐的合成", 《精细化工中间体》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111848606B (en) | 2023-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111848727B (en) | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl nonpolar amino acid | |
| CN108948146B (en) | 1R-methyl-beta-tetrahydrocarboline acyl-K (ARPAK) -RGDV, and synthesis, activity and application thereof | |
| CN108929372B (en) | 1R-methyl-beta-tetrahydrocarboline acyl-K (GRPAK) -RGDV, and synthesis, activity and application thereof | |
| CN111848606B (en) | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formylglycine and alanine | |
| CN111848724B (en) | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl acidic amino acid | |
| CN111848730B (en) | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl polar amino acid | |
| CN106608905B (en) | tetrahydroisoquinoline-3-formyl-K (GRPAK) RGDV, and synthesis, activity and application thereof | |
| CN106317196B (en) | Imidazopyridine formyl-K (K) -AA1-AA2-AA3-AK, its synthesis, activity and use | |
| CN111848723B (en) | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formylmethionine and proline | |
| CN111848729B (en) | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl asparagine and glutamine | |
| CN111848728B (en) | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl-L-histidine | |
| CN106432417B (en) | Pentamethoxychromoamino carbonyl propionyl-RPAK, preparation, activity and application thereof | |
| CN111848725B (en) | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl basic amino acid | |
| CN111848726B (en) | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl aromatic amino acid | |
| CN110577572B (en) | Synthesis, activity and application of 1S-methyl-beta-tetrahydrocarboline acyl-K (PAK) | |
| CN108948155B (en) | 1R-methyl-beta-tetrahydrocarboline acyl-K (QRPAK) -RGDV, and synthesis, activity and application thereof | |
| CN108948145B (en) | 1R-methyl-beta-tetrahydrocarboline acyl-K (PAK) -RGDV, and synthesis, activity and application thereof | |
| CN106608901B (en) | Dihydroxydimethyltetrahydroisoquinoline-3-formyl-Lys (Lys-Ala), and synthesis, activity and application thereof | |
| CN106699844B (en) | The-RGDVGRPAK decapeptide, and preparation, activity and application thereof | |
| CN106432414B (en) | Pentamethoxytryptophane-KAPKAP, its preparation, activity and use | |
| CN110577578B (en) | Synthesis, activity and application of 1S-methyl-beta-tetrahydrocarboline acyl-K (RPAK) | |
| CN106432418B (en) | Pentamethoxychromoamino carbonyl propionyl-PAKPAK, its preparation, activity and application | |
| CN110615828B (en) | 1S-methyl-beta-tetrahydrocarboline acyl-K and synthesis, activity and application thereof | |
| CN110577575B (en) | 1S-methyl-beta-tetrahydrocarboline acyl-K (ARPAK) -RGDV, and synthesis, activity and application thereof | |
| CN110577574B (en) | 1S-methyl-beta-tetrahydrocarboline acyl-K (PAK) -RGDV, and synthesis, activity and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |